UCB and Biogen Announce Topline Results from a Phase 2b Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. DLMAF

Go back to UCB and Biogen Announce Topline Results from a Phase 2b Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus
BIOGEN IDEC Inc. (NASDAQ: BIIB) Delayed: 200.05 +0.09 (0.05%)
Previous Close $199.96    52 Week High $333.65 
Open $200.57    52 Week Low $223.02 
Day High $203.45    P/E 25.61 
Day Low $199.06    EPS $7.81 
Volume 837,294